Company Profile
Lyell Immunopharma Stock Price, News & Catalysts
- Ticker:
- LYEL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
15.53 USD (+1.17%)
Close
Last updated: August 21, 2026
347M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, LYEL closed up 1.17% at $15.53. No new same-company headline was identified in the current news window.
Company overview
Next-Generation CAR-T Therapies
Lyell Immunopharma develops engineered CAR-T cell therapies intended to improve response depth, durability and activity in hematologic and solid tumors.
Ronde-cel
Ronde-cel is an autologous CAR-T product with an OR-gated design targeting either CD19 or CD20. Its manufacturing process enriches less-differentiated T cells to support persistence in large B-cell lymphoma.
Pivotal LBCL Programs
PiNACLE is a pivotal single-arm study in third- or later-line large B-cell lymphoma. PiNACLE-H2H is a randomized Phase 3 trial comparing ronde-cel directly with established CD19 CAR-T therapies in second-line disease.
LYL273
LYL273 is a separate engineered cell therapy in Phase 1 development for metastatic colorectal cancer, extending Lyell's platform into solid tumors.
Future catalysts
- Additional PiNACLE data in the second half of 2026.
- LYL273 safety update in the first half of 2026 and clinical-outcomes update in the second half of 2026.
- Pivotal PiNACLE data around mid-2027, followed by a planned BLA submission in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lyell Immunopharma (LYEL)?
Lyell Immunopharma (LYEL) most recently closed at 15.53 USD, a +1.17% move versus the previous session.
What is the market cap of Lyell Immunopharma (LYEL)?
Lyell Immunopharma currently has a market capitalization of 347M USD on BioPharmSignal.
What does Lyell Immunopharma do?
Next-Generation CAR-T Therapies Lyell Immunopharma develops engineered CAR-T cell therapies intended to improve response depth, durability and activity in hematologic and solid tumors. Ronde-cel Ronde-cel is an autologous CAR-T product with an OR-gated design targeting either CD19 or CD20. Its manufacturing process enriches less-differentiated T cells to...
On which exchange is LYEL stock listed?
Lyell Immunopharma (LYEL) is associated with NASDAQ, United States, Biopharma.
What is CAR-T?
Next-Generation CAR-T Therapies Lyell Immunopharma develops engineered CAR-T cell therapies intended to improve response depth, durability and activity in hematologic and solid tumors.
Which conditions is Lyell Immunopharma targeting with CAR-T?
Lyell Immunopharma is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Lyell Immunopharma describe recent progress with CAR-T?
Additional PiNACLE data in the second half of 2026. LYL273 safety update in the first half of 2026 and clinical-outcomes update in the second half of 2026. Pivotal PiNACLE data around mid-2027, followed by a planned BLA submission in 2027.
What is Next-Generation?
Next-Generation CAR-T Therapies Lyell Immunopharma develops engineered CAR-T cell therapies intended to improve response depth, durability and activity in hematologic and solid tumors.